Genetic variations in benzene metabolism and susceptibility to multiple myeloma

Leuk Res. 2007 Jun;31(6):759-63. doi: 10.1016/j.leukres.2006.07.012. Epub 2006 Sep 1.

Abstract

We have previously shown that deficiency in the biotransformation enzyme glutathione-S-transferase theta (GSTT1) is a risk factor for multiple myeloma (MM). The present case-control study of 102 MM patients and 205 controls revealed a significant trend in increasing risk of MM with inheritance of multiple putative 'high risk' genetic variants in related pathways of benzene detoxification. Individuals who carried polymorphisms for GSTT1 null and/or high activity microsomal epoxide hydrolase (mEH 113YY+139HR or 113YY+139RR or 113YH+139RR) and/or low activity NAD(P)H:quinone oxidoreductase 1 (NQO1 187PS/SS) were 1.65, 2.49 and 13 times more likely to have MM (P(trend)=0.001).

Publication types

  • Clinical Trial
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Benzene / metabolism
  • Case-Control Studies
  • Epoxide Hydrolases / genetics*
  • Epoxide Hydrolases / metabolism
  • Female
  • Genetic Predisposition to Disease*
  • Glutathione Transferase / genetics*
  • Glutathione Transferase / metabolism
  • Humans
  • Male
  • Middle Aged
  • Multiple Myeloma / enzymology
  • Multiple Myeloma / genetics*
  • NADH, NADPH Oxidoreductases / genetics*
  • NADH, NADPH Oxidoreductases / metabolism
  • Polymorphism, Single Nucleotide*
  • Risk Factors

Substances

  • NADH, NADPH Oxidoreductases
  • glutathione S-transferase T1
  • Glutathione Transferase
  • Epoxide Hydrolases
  • Benzene